Abstract
We previously reported that simvastatin, an inhibitor of HMG-CoA reductase, inhibits atherosclerosis in rats. The present study was designed to investigate the effect of simvastatin on mouse peritoneal macrophage foam cell formation, the early feature of atherosclerosis and explore its mechanisms. The results showed that simvastatin decreased cholesterol content and DiI-oxLDL uptake, reduced the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the medium, down-regulated the mRNA and protein expression of CD36 and reduced the mRNA expressions of peroxisome proliferator-activated receptor gamma (PPARγ), TNF-α and IL-6 in macrophages treated with oxidized low density lipoprotein (oxLDL). However, PPARγ agonist troglitazone partly abolished the effects of simvastatin on foam cells.
In addition, simvastatin reduced the protein expression of calpain-1, Ca 
Introduction
Atherosclerotic cardiovascular disease (CVD) is the prime cause of mortality in developed countries, and its incidence in developing countries has been increasing recently (Zelicoff 2015) . Oxidative stress has been involved in the development of atherosclerosis (Villa-Bellosta et al. 2013) . Macrophage foam cells filled with oxidized lipids mainly derived from oxidized low density lipoprotein (oxLDL) are the characteristics of early atherosclerotic lesion (Barzilay et al. 2015) . OxLDL is taken up by macrophages via the scavenger receptors including CD36, SR-A and LOX-1 (Ogura et al. 2016) . Mice lacking CD36 do not accumulate esterified cholesterol derived from oxLDL (Kunjathoor et al. 2002) and develop fewer atherosclerotic lesions. Thus, the development of drugs that down-regulate CD36 expression could possibly provide a strong basis for a novel anti-atherosclerotic therapy. We previously reported that Tanshinone IIA extracted from Salvia miltiorrhiza Bunge (Danshen) and vitamin E inhibit the atherosclerosis in apolipoprotein E knockout (ApoE KO) mice through down-regulation of CD36 (Villa-Bellosta et al. 2013 ).
It has been reported that atherosclerosis is predominantly an inflammatory process (Gu et al. 2011) . Various studies have highlighted that pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) are the upstream inflammatory cytokines that play important role in propagating the downstream inflammatory response responsible for atherosclerosis (Koga et al. 2004) . Considering the importance of TNF-α and IL-6 in the development of coronary artery disease, targeting their actions could prove to be beneficial.
Peroxisome proliferator-activated receptor gamma (PPARγ) is reportedly implicated in the regulation of CD36 by oxLDL (Nicholson 2004; Rutsch et al. 2011) .
PPARγ is a member of a nuclear hormone superfamily that heterodimerizes with the retinoid X receptor (RXR) (Tontonoz et al. 1995) . We previously reported that PPARγ agonists 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and troglitazone dose-dependently abolished the down-regulation of CD36 expression by Tanshinone Calpain, a calcium-dependent cysteine protease, has been shown to be involved in the pathogenesis of atherosclerosis (Baldi et al. 2013; Li et al. 1991) . Inhibition of calpain attenuates atherosclerosis in low density lipoprotein (LDL) receptor deficient mice (Devaraj et al. 2007 ). Calpain-1 and -2, the two major isoforms of the calpain family, are ubiquitously expressed (Shanahan et al. 2011) . We and others reported that simvastatin, an inhibitor of HMG-CoA reductase, inhibits atherosclerosis in rabbits, rats and mice (Song et al. 2011; Tang et al. 2006 ).
However, the precise mechanism of the inhibition remains to be investigated. The study demonstrated that simvastatin down-regulates the expression of CD36 at the mRNA and protein levels (Devaraj et al. 2001) , suggesting a potential novel target for simvastatin in the prevention of atherosclerosis. The present study was designed to investigate the effects of simvastatin on foam cell formation and to further explore the mechanisms with focus on the calpain-1/PPARγ/CD36 pathway. The results showed that simvastatin inhibits the formation of foam cells by down-regulating mRNA and protein levels of CD36, which might be attributed to the calpain-1 inhibition-mediated antagonism of PPARγ. LMU-2014-118). The isolation and culture of macrophages from mouse peritoneal cavities was carried out as reported previously (Tang et al. 2011) . Macrophages were infected with adenoviral vectors containing mouse calpain-1 gene (Ad-Cal, provided
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Chemicals and reagents
by Professor Jinshen Huang in Liaoning Medical University) or beta-gal (Ad-gal, Vector Biolabs) as a control at a multiplicity of infection of 10 PFU/cell. Adenovirus mediated gene transfer was implemented as previously described (Chen et al. 2014 ).
Over-expression of calpain-1 in macrophages was confirmed by Western blot. All experiments were performed after 24 hours of adenoviral infection.
Preparation of oxLDL
Human plasma was purchased from the Blood Perfusion Center of the First Affiliated Hospital of Liaoning Medical University after approval of the Human Investigation Committee of the Liaoning Medical University, China (Permit Number:
LMU-2013-138). The method for oxidation of LDL was described previously (Tang et al. 2011) . Briefly, LDL was separated from human plasma by sequential flotation in NaBr solution containing 1 mg/ml EDTA. Cu 2+ -modified LDL (1.0 mg of protein/ml) was prepared by exposure of LDL to 5 mM CuSO4 for 18 h at 37 °C. The extent of LDL oxidation was determined by thiobarbituric acid reactive substances (TBARS) D r a f t -6 -and the value of TBARS of oxLDL used in our experiment was 8.8 vs 0.7 nmol/100 mg protein in the native-LDL preparation.
Preparation of DiI-oxLDL
The method for preparation of DiI-LDL was described previously (Tang et al. 2011 ).
Cholesterol levels in macrophages
Macrophages were pre-incubated with vehicle or simvastatin (10 µM) in the presence or absence of troglitazone (50µM) for 24 hours, and then incubated with oxLDL (50 µg/ml) for another 24 hours. The cholesterol mass was quantified by enzymatic fluorometric micro-assay as described previously (Tang et al. 2011) .
Fluorescence was measured with a FLUO star OPTIMA (BMG LABTECH, Germany) (excitation, 320 nm; emission, 410 nm). Cholesterol content in macrophages was expressed as µg/(mg cell protein).
DiI-oxLDL uptake by macrophages
Macrophages were pre-incubated with vehicle or simvastatin (10 µM ) in the presence or absence of troglitazone (50µM) for 24 hours and then incubated with DiI-oxLDL (50 µg/mL) for another 24 hours. The cells were washed and then investigated by fluorescence microscopy as described previously (Tang et al. 2011 ).
Contents of TNF-α and IL-6 in medium of macrophage
Medium of macrophages were used for measuring the contents of TNF-α and IL-6
by Enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems 
Protein expression of CD36 and calpain-1
Protein expression of CD36 and calpain-1 in macrophages was determined by
Western blot as described previously (Tang et al. 2011 ).
Statistical analysis
Data are presented as the mean ±SEM and analyzed by one-way ANOVA and the 
Results
Simvastatin reduces cholesterol content and DiI-oxLDL uptake in macrophages
Macrophages uptaking oxLDL become foam cells. The present study showed that the cholesterol content in oxLDL-treated macrophages increased significantly compared with that in macrophages treated with vehicle. However, the increase in 
Discussions
The present study demonstrated that simvastatin inhibits the foam cells formation, inhibition-mediated antagonism of PPARγ. This in vitro study might add new mechanism by which simvastatin inhibits the atherosclerosis reported previously in our laboratory and others (Liu et al. 2013; Song et al. 2011; Tang et al. 2006) .
CD36 is an 88-kD membrane glycoprotein and expressed by monocytes/macrophages, vasculature endothelial cells and smooth muscle cells (Talle et al. 1983 ). Functional and structural characterization showed that CD36 belongs to the scavenger receptor class B family with a capacity to bind oxLDL (McGregor et al. 1989 ). The importance of monocytic CD36 in the initiation and perpetuation of atherosclerotic lesions was proved by the reduced size of vascular lesions when CD36
was inactivated in ApoE deficient animals (Kunjathoor et al. 2002; Wallin et al. 2001 ). Many reports reveal that the mechanism by which oxLDL induces CD36 is due to its ability to activate the PPARγ (Rutsch et al. 2011; Tontonoz et al. 1995; Tontonoz et al. 1998) . PPARγ is a member of a nuclear hormone superfamily that heterodimerizes with RXR. These proteins are transcriptional regulators of genes that encode proteins involved in adipogenesis and lipid metabolism (Tontonoz et al. 1995) . (Lomashvili et al. 2008) and that oleoylethanolamide inhibits atherosclerosis in ApoE KO mice by down-regulating the mRNA expression of TNF-α and IL-6 in atherosclerotic tissue (Wallin et al. 2001 ).
Calpain, a calcium-dependent cysteine protease, has been shown to play important role in inflammation and atherosclerosis (Miyazaki et al. 2013; Miyazaki et al. 2011) .
Calpains induce proteolytic degradation of ATP-binding cassette transporter A1
(ABCA1) and G1 (ABCG1) in monocytes/macrophages, subsequently causing the impaired cholesterol efflux and subsequent macrophage foam cell formation (Tanaka et al. 2010; Wang et al. 2003 ). Studies at the animal level showed that inhibition of calpain attenuates atherosclerosis in both ApoE KO and LDL receptor deficient mice (Miyazaki et al. 2011; Subramanian et al. 2012) . These studies suggested the potency of calpain as a molecular target in atherosclerosis. Calpains get involved in acute inflammatory processes via the activation of NF-κB Schibler et al. 1968) . Specifically, the protein expression of calpain-1 instead of calpain-2 has been shown to be positively correlated with the contents of TNF-α and IL-6 and the In summary, the present study demonstrated that simvastatin inhibits the macrophage foam cell formation, which might be largely attributed to calpain-1 inhibition-mediated regulation of PPARγ/CD36 pathway.
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